A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates

Simply Wall St.02-03 22:15

AdvertisementWhy Soleno Therapeutics Is Back on Investors’ Radar Soleno Therapeutics (SLNO) is drawing fresh attention after describing 2025 as a transformational year, highlighting early traction for...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608081528?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-03 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608081528","market":"hk","top_or_hot":-1,"title":"A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Soleno Therapeutics Is Back on Investors’ Radar Soleno Therapeutics (SLNO) is drawing fresh attention after describing 2025 as a transformational year, highlighting early traction for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/a-look-at-soleno-therapeutics-slno-valuation-after-vykat-xr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/a-look-at-soleno-therapeutics-slno-valuation-after-vykat-xr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Soleno Therapeutics Is Back on Investors’ Radar Soleno Therapeutics (SLNO) is drawing fresh attention after describing 2025 as a transformational year, highlighting early traction for...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/a-look-at-soleno-therapeutics-slno-valuation-after-vykat-xr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/a-look-at-soleno-therapeutics-slno-valuation-after-vykat-xr","article_id":"2608081528","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/a-look-at-soleno-therapeutics-slno-valuation-after-vykat-xr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608081528","pubTimestamp":1770128107,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Soleno Therapeutics Is Back on Investors’ Radar\nSoleno Therapeutics (SLNO) is drawing fresh attention after describing 2025 as a transformational year, highlighting early traction for VYKAT XR, and flagging upcoming full financial results alongside a busy investor conference schedule.\nSee our latest analysis for Soleno Therapeutics.\nThe latest 9.75% 1 day share price gain to US$42.32 comes after management framed 2025 as transformational and highlighted early VYKAT XR traction. However,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLNO":"Soleno Therapeutics"},"translate_title":"VYKAT XR推出后Soleno Therapeutics(SLNO)估值以及即将到来的2025年业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":1.5},"content_text":"AdvertisementWhy Soleno Therapeutics Is Back on Investors’ Radar Soleno Therapeutics (SLNO) is drawing fresh attention after describing 2025 as a transformational year, highlighting early traction for VYKAT XR, and flagging upcoming full financial results alongside a busy investor conference schedule. See our latest analysis for Soleno Therapeutics. The latest 9.75% 1 day share price gain to US$42.32 comes after management framed 2025 as transformational and highlighted early VYKAT XR traction. However, recent 30 day and year to date share price returns of around 10% declines contrast with a very large 3 year total shareholder return, which suggests that momentum has cooled recently after a strong run. If this kind of rare disease story has your attention, it could be a good moment to see what else is setting up in healthcare stocks. With Soleno still loss making, recent share price declines, and an analyst target that sits far above the current US$42.32 level, you have to ask whether there is mispricing here or whether the market is already factoring in future growth. Most Popular Narrative: 70.6% Undervalued With Soleno Therapeutics last closing at $42.32 and the most followed narrative pointing to a fair value of about $143.71, the gap between price and narrative expectations is wide and raises questions about what is priced in today.  First mover position with the only FDA approved therapy for PWS related hyperphagia in patients 4 years and older, supported by Phase III data in 127 patients and over 400 patient years of exposure, can help sustain pricing power and support revenue resilience and potential scale benefits for earnings.  Read the complete narrative. Want to see what kind of revenue curve and margin profile sits behind that fair value, and how far profitability is expected to swing over the next few years? The narrative lays out a bold earnings ramp, a richer margin structure and a valuation multiple that might surprise you if you usually associate those numbers with much larger biopharma names. Result: Fair Value of $143.71 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this bullish setup can quickly be challenged if sentiment around VYKAT XR safety hardens further, or if European approval and launch timelines slip. Find out about the key risks to this Soleno Therapeutics narrative. Another Angle on Valuation The bullish narrative leans on earnings forecasts and a high fair value, but our DCF model paints an even starker picture, with a fair value of about $436.04 versus the current $42.32. That points to very large implied upside, but how comfortable are you with the assumptions needed to get there? Look into how the SWS DCF model arrives at its fair value. SLNO Discounted Cash Flow as at Feb 2026 Build Your Own Soleno Therapeutics Narrative If you see the story differently, or want to stress test the assumptions yourself, you can create your own view in minutes: Do it your way. A great starting point for your Soleno Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If Soleno has sparked your interest, do not stop there. Use this momentum to scan for other setups that could fit your style before the crowd catches on.  Target growth at the smaller end of the market by reviewing these 3533 penny stocks with strong financials that already show stronger fundamentals than many expect from low priced names. Position yourself closer to long term tech trends by examining these 24 AI penny stocks that tie artificial intelligence themes to listed companies you can actually research. Focus on price versus cash flow potential by filtering for these 871 undervalued stocks based on cash flows that might offer more attractive entry points than widely followed large caps.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608081528","isCrawlerRequest":true}